Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19

ChemSitu Microfluidic Technology for In Situ Mass Spectrometric Characterization of Microfluidic Devices

Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies and materials for their technological significance that are available for sale or license. The R&D 100 Awards have long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This year's R&D 100 2020 winner is listed below in their respective category.
 
Category: Analytical/Test
Developers: Oak Ridge National Laboratory
United States

Product Description:The ChemSitu Microfluidic Technology for In Situ Mass Spectrometric Characterization of Microfluidic Devices, from Oak Ridge National Laboratory, is a microfluidic chip and chemical analysis system that allows in situ chemical characterization at any point within the device. It provides a new analytical capability to solve the problem of elucidating the complex chemistry occurring within microfluidic devices. With the advent and continued growth of biology-on-a-chip devices, the ability to understand the chemical composition of such systems in situ is becoming more critical. Society and industry rely extensively on our chemical understating of living systems to diagnose disease and to develop new and more effective therapeutics. Industries such as oncology and pharmacokinetics need to evaluate therapeutic effectiveness in living systems, and biology-on-a-chip devices with a broad chemical analysis capability represent an ethical, cost-effective means to assess them. The collective features of the ChemSitu microfluidic technology make it more versatile than any other chemical analysis capability in the microfluidic device market, opening the door to numerous applications requiring mass spectrometric chemical analysis of such devices.

Photo 1

Back to full list of 2020 R&D Winners
Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19